Publikationen, an denen er mitarbeitet Jesús Bañales Asurmendi (29)

2024

  1. Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1

    JHEP Reports, Vol. 6, Núm. 1

  2. MCPIP1 Inhibits Hepatic Stellate Cell Activation in Autocrine and Paracrine Manners, Preventing Liver Fibrosis

    Cellular and Molecular Gastroenterology and Hepatology, Vol. 17, Núm. 6, pp. 887-906

  3. SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer

    Cell Reports, Vol. 43, Núm. 3

2022

  1. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions

    Gut, Vol. 71, Núm. 8, pp. 1669-1683

  2. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

  3. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models

    Journal of Hepatology, Vol. 77, Núm. 1, pp. 177-190

2021

  1. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma

    Hepatology, Vol. 73, Núm. 6, pp. 2380-2396

  2. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted

    Journal of Hepatology, Vol. 75, Núm. 2, pp. 363-376

  3. Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis

    Molecular Metabolism, Vol. 53

  4. The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma: Diagnosis of NAFLD-HCC utilising serum lipidomics

    EBioMedicine, Vol. 73

2020

  1. A novel serum metabolomic profile for the differential diagnosis of distal cholangiocarcinoma and pancreatic ductal adenocarcinoma

    Cancers, Vol. 12, Núm. 6

  2. Dual pharmacological targeting of hdacs and pde5 inhibits liver disease progression in a mouse model of biliary inflammation and fibrosis

    Cancers, Vol. 12, Núm. 12, pp. 1-27

  3. Multi‐omics integration highlights the role of ubiquitination in ccl4‐induced liver fibrosis

    International Journal of Molecular Sciences, Vol. 21, Núm. 23, pp. 1-19

  4. Pilot multi-omic analysis of human bile from benign and malignant biliary strictures: A machine-learning approach

    Cancers, Vol. 12, Núm. 6, pp. 1-30

  5. Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets

    Liver International, Vol. 40, Núm. 7, pp. 1670-1685

  6. S-adenosyl-L-methionine (SAMe) halts the autoimmune response in patients with primary biliary cholangitis (PBC) via antioxidant and S-glutathionylation processes in cholangiocytes

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1866, Núm. 11

2019

  1. Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy

    Hepatology, Vol. 70, Núm. 4, pp. 1246-1261

  2. Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma

    Hepatology, Vol. 69, Núm. 2, pp. 587-603

  3. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib

    British Journal of Pharmacology, Vol. 176, Núm. 6, pp. 787-800

  4. Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage

    Gut, Vol. 68, Núm. 3, pp. 533-546